Most of the targeted therapies for osteosarcoma have focused on signaling pathways such as human epidermal growth factor receptor (HEGR2), insulin-like growth factor 1(IGF1), and mammalian target of rapamycin (mTOR), which appear overactive in osteosarcoma tumors [12,15]. Here, MTOR is linked to osteosarcoma.